124 related articles for article (PubMed ID: 23752435)
21. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
[TBL] [Abstract][Full Text] [Related]
22. The increasing diversity of KRAS signaling in pancreatic cancer.
Siveke JT
Gastroenterology; 2014 Oct; 147(4):736-9. PubMed ID: 25167989
[No Abstract] [Full Text] [Related]
23. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
24. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
25. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
[TBL] [Abstract][Full Text] [Related]
26. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
[TBL] [Abstract][Full Text] [Related]
27. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.
Daye D; Wellen KE
Semin Cell Dev Biol; 2012 Jun; 23(4):362-9. PubMed ID: 22349059
[TBL] [Abstract][Full Text] [Related]
28. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
29. IDH Inhibitors Target Common Glioma Mutation.
Cancer Discov; 2019 Aug; 9(8):992. PubMed ID: 31217295
[TBL] [Abstract][Full Text] [Related]
30. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
Chaturvedi A; Goparaju R; Gupta C; Weder J; Klünemann T; Araujo Cruz MM; Kloos A; Goerlich K; Schottmann R; Othman B; Struys EA; Bähre H; Grote-Koska D; Brand K; Ganser A; Preller M; Heuser M
Leukemia; 2020 Feb; 34(2):416-426. PubMed ID: 31586149
[TBL] [Abstract][Full Text] [Related]
31. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
32. Exploiting the bad eating habits of Ras-driven cancers.
White E
Genes Dev; 2013 Oct; 27(19):2065-71. PubMed ID: 24115766
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of tumor-induced gene expression changes in the human metabolic network.
Hu J; Locasale JW; Bielas JH; O'Sullivan J; Sheahan K; Cantley LC; Vander Heiden MG; Vitkup D
Nat Biotechnol; 2013 Jun; 31(6):522-9. PubMed ID: 23604282
[TBL] [Abstract][Full Text] [Related]
34. Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach.
Chen L; Cui H
Int J Mol Sci; 2015 Sep; 16(9):22830-55. PubMed ID: 26402672
[TBL] [Abstract][Full Text] [Related]
35. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.
Ma Y; Gu Y; Zhang Q; Han Y; Yu S; Lu Z; Chen J
Mol Cancer Ther; 2013 Mar; 12(3):286-94. PubMed ID: 23288781
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.
Gaglio D; Metallo CM; Gameiro PA; Hiller K; Danna LS; Balestrieri C; Alberghina L; Stephanopoulos G; Chiaradonna F
Mol Syst Biol; 2011 Aug; 7():523. PubMed ID: 21847114
[TBL] [Abstract][Full Text] [Related]
37. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
38. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
39. IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.
Pronier E; Levine RL
Cancer Cell; 2015 Mar; 27(3):323-5. PubMed ID: 25759018
[TBL] [Abstract][Full Text] [Related]
40. Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer.
Baer R; Pyronnet S; Guillermet-Guibert J
Clin Res Hepatol Gastroenterol; 2013 Sep; 37(4):320-1. PubMed ID: 23746401
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]